EGALET CORP Common Stock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch EGLTQ and buy or sell other stocks, ETFs, and their options commission-free!

About EGLTQ

Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. 

CEO
Todd N. Smith
CEOTodd N. Smith
Employees
Employees
Headquarters
Wayne, Pennsylvania
HeadquartersWayne, Pennsylvania
Founded
2013
Founded2013
Employees
Employees

EGLTQ Key Statistics

Market cap
465.50K
Market cap465.50K
Price-Earnings ratio
-0.01
Price-Earnings ratio-0.01
Dividend yield
Dividend yield
Average volume
116.29K
Average volume116.29K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.95
52 Week high$0.95
52 Week low
$0.001
52 Week low$0.001

Stock Snapshot

As of today, EGALET CORP Common Stock(EGLTQ) shares are valued at $0.01. The company's market cap stands at 465.5K, with a P/E ratio of -0.01.

On 2026-03-10, EGALET CORP Common Stock(EGLTQ) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for EGALET CORP Common Stock(EGLTQ) stock has reached 0, versus its average volume of 116.29K.

The stock's 52-week range extends from a low of $0.00 to a high of $0.95.

The stock's 52-week range extends from a low of $0.00 to a high of $0.95.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.